Temodar has some activity in sarcomas as a singel agent. However, while not particularly effective, it is thought to have a place in palliation of resistant disease. Several phase II trials have been performed.
Temozolomide is a radiosensitizer that is well tolerated and has modest side effects. It has been studied with radiation in the end stage sarcoma situations with or without radiation for palliation and such use is supported by several phase II trials
Woll, P.J., I. Judson, S.M. Lee, S. Rodenhuis, O.S. Nielsen, J.M. Buesa, Lorigan, PC, S. Leyvraz, C. Hermans, G.M. van, and J. Verweij. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 35: 410-412, 1999.
Aksoy S, Abali H, Kilickap S, et al. Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma. J Neurooncol. 2005; 71:333-334.
Taub, R.N., M. Keohan, M. Plitsas, and R. Scheinmann.
Phase II study of temozolomide in advanced sarcomas. Proc Amer Soc Clin Oncol 19: Abstract 2185;2000.
Nagasubramanian R, Dolan ME. Temozolomide: realizing the promise and potential. Curr Opin Oncol. 2003;15:412-418.